Drugs / QR-333
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00568035 Comparator | Dec 2006 → Nov 2008 | diabetic neuropathy | Quigley Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QR-333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00568035 ↗ |
| Route | Topical | “QR-333 or placebo will be applied three times a day for 12 weeks” NCT00568035 ↗ |